Skip to main content
OpenTrials

Clinical trial condition

Paraproteinemias

Explore clinical trials studying Paraproteinemias. Study availability and eligibility vary by location and protocol.

3,043 public trials 577 recruiting studies
Refine in advanced search Browse all conditions

Paraproteinemias trial results

Recruiting

A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma

NCT04973605

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • University of Alabama At Birmingham Hospital Birmingham, Alabama, United States
  • City of Hope National Medical Center Duarte, California, United States
  • City of Hope Irvine Lennar Irvine, California, United States
  • University of Miami Miami, Florida, United States
View all 78 locations
View Trial Details
Recruiting

Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

NCT06297226

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +16 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • Banner MD Anderson Cancer Center Gilbert, Arizona, United States
  • University of Arkansas for Medical Sciences Little Rock, Arkansas, United States
  • UCLA Hematology/Oncology - Westwood (Building 200 Suite 214) Los Angeles, California, United States
View all 52 locations
View Trial Details
Recruiting

A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma

NCT07455851

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • Prince of Wales Hospital Randwick, New South Wales, Australia
  • Illawarra Cancer care centre, Wollongong Hospital Wollongong, New South Wales, Australia
  • Royal Adelaide Hospital Adelaide, South Australia, Australia
  • Peter MacCallum Cancer Centre Melbourne, Victoria, Australia
View Trial Details
Recruiting

Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma

NCT07555938

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • City of Hope National Medical Center Duarte, California, United States
  • City of Hope - Lennar Foundation Cancer Center Irvine, California, United States
  • Emory University Hospital Midtown Atlanta, Georgia, United States
  • Novant Health Cancer Institute Charlotte, North Carolina, United States
View all 75 locations
View Trial Details
Recruiting

A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

NCT05006716

Conditions
B-cell Malignancy, Blood Protein Disorders, Cardiovascular Diseases, +37 more
Locations
  • University of Alabama At Birmingham Hospital Birmingham, Alabama, United States
  • Mayo Clinic Phoenix Phoenix, Arizona, United States
  • Honor Health Research Institute Scottsdale, Arizona, United States
  • University of Arizona Cancer Center Tucson, Arizona, United States
View all 115 locations
View Trial Details
Recruiting

A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma

NCT06049290

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • The First Affiliated Hospital of Wannan Medical College Wuhu, Anhui, China
  • Peking University People's Hospital Beijing, Beijing Municipality, China
  • The First Affiliated Hospital of Xiamen University Xiamen, Fujian, China
  • Sun Yat-sen University Cancer Center Guangzhou, Guangdong, China
View all 21 locations
View Trial Details
Recruiting

A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

NCT05519085

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +17 more
Locations
  • Local Institution - 0366 Los Alamitos, California, United States
  • Local Institution - 0272 San Diego, California, United States
  • Local Institution - 0273 West Hollywood, California, United States
  • Local Institution - 0381 Aurora, Colorado, United States
View all 266 locations
View Trial Details

Related conditions